Summary

Contact us
The regulation harmonizes regulations on a European scale, which is a major issue in terms of the health of populations across Europe on the one hand, and in terms of innovation on the other.

The regulation creates, in very concrete terms, for example:

• An infrastructure enabling the sharing of health data contained in medical records, respecting the rights of individuals, for cross-border care of people during their travels in Europe;

• An infrastructure, procedures for accessing harmonized and regulated data in member states, and catalogs of data available to facilitate the secondary reuse of health data that has been previously anonymized or pseudonymized.

The regulation strengthens and harmonizes, in addition to the GDPR, the rights of individuals concerning health data: the right of direct access to medical records, the right to object to the processing of health data, settings for access to this data, enhanced information, and facilitation of the exercise of rights for individuals, and rules for data localization.It also provides for a robust framework of European and national governance for digital health. It requires the creation, in each member state, of national authorities competent to support and control the proper application of the regulation. It strengthens European governance of digital health by replacing the eHealth network, co-chaired by France, with a committee of the EHDS with a comitology involving all stakeholders in the decisions (patients, health professionals, researchers, industrialists, institutional representatives, etc.).

The European Commission will establish the central infrastructure and services supporting the EHDS.In the medium term, the regulation also provides for the possibility of connection for countries and organizations based outside the EU, under conditions of guaranteed security and data protection.Its implementation will be spread over the next 2 to 6 years and will require adjustments to existing regulations in France, particularly concerning the reuse of health data (secondary use).

Contact us

FAQs

Our frequently questions

No items found.

Find out how iliomad can help your company.

[Map placeholder]
Only visible in production
38.709099
-39.182035
1.6
6d17042a3425c5b3
Your message has been received!
We'll get back to you as soon as possible.
Something went wrong, please try again.
Home

Discover our latest articles

View All Blog Posts
Diagram illustrating the EDPB three-criteria anonymisation test applied to clinical trial datasets under GDPR, with icons for record isolation, linkage and inference
July 13, 2026
DPIA
AI
Testimonial
EU Privacy Law
Regulations & Guidelines

EDPB Anonymisation Guidelines 2026 and Clinical Trial Data: What Life Sciences Organisations Must Know

EDPB Guidelines 02/2026 on anonymisation set new standards for clinical trial data. Learn the three-criteria test, enforcement lessons and compliance steps. iliomad.

Abstract digital network connecting a hospital, a regulatory building and a courtroom, representing AI governance, health data privacy and transatlantic data transfer risks in 2026
July 8, 2026
Healthtech
Regulations & Guidelines
DPIA
Regulation
LLMS

AI Triage, Biopharma Workbenches and Crumbling Data Bridges: iliomad Weekly Digest

NHS AI triage, Anthropic Claude Science, medical AI privacy risks, MHRA GxP guidance, EDPS ADM checklist and the EU-US data transfer threat explained.

A clinical data reviewer examining an automated decision output on a screen, representing human oversight in GDPR clinical trials under the EDPS ADM checklist framework
July 6, 2026
GDPR
Regulation
Clinical Trials
US Privacy Law
EU Privacy Law

Human Intervention in Automated Decision-Making: What the EDPS Checklist Means for Life Sciences

The EDPS checklist on human intervention in automated decision-making carries direct implications for GDPR clinical trials. Learn what effective oversight requires.